Besremi Achieves Strong Market Growth Amid Rising Demand For Polycythemia Vera Treatment
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...
Myelofibrosis (MF) Market Epidemiology and Forecast 2034: JAKAFI Leads Myelofibrosis Market, But New Therapies Poised to Disrupt by 2034
The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...